Diagnosis of myelodysplastic syndromes (MDS) could be difficult. We explored the usefulness of the enumeration of maturing B-lineage precursors (hematogones) by multiparameter flow cytometric analysis in the diagnosis of MDS in bone marrow (BM) specimens. We evaluated 111 MDS, 120 non-MDS

Thus, hematogone enumeration may serve as a biomarker to aid in the diagnosis of MDS. Interestingly, the percentage of hematogones was not significantly different between MDS subgroups or patients with MDS with and without chromosomal abnormalities, implying that a defect in maturing B-cell precursors may be an early event in the pathogenesis of MDS.
Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell diseases characterized by dysplasia, ineffective hematopoiesis in one or more of the major myeloid cell lines, and progression to acute myelogenous leukemia. [1] [2] [3] Despite the well-established diagnostic criteria and everexpanding battery of cytogenetic and molecular diagnostic assays, diagnosis of MDS, especially low-grade MDS, is not always straightforward. The reasons for such difficulty are multiple, including the significant interobserver disparity in documenting the extent of dysplasia, especially when dysplasia is mild to moderate, 4 and frequent lack of detectable chromosomal abnormalities. 5 Moreover, the morphologic dysplastic features do not in themselves establish the diagnosis. Conditions other than MDS could induce dysplastic changes (eg, nutritional deficiency, congenital hematologic disorders, toxin exposure, medication effects, and viral infections). This highlights the need for a reliable diagnostic biomarker to aid in the diagnosis of MDS, in particular for low-grade and karyotypically normal MDS.
Recent complementary DNA microarray analyses on CD34+ hematopoietic progenitor cells in patients with MDS have found that MDS, including early-stage/low-grade MDS, is characterized by a B-cell progenitor defect. [6] [7] [8] Many of the genes involved in B-lymphocyte development are down-regulated. This was validated by the finding of reduced maturing B-lineage precursors (hematogones) by flow cytometric analysis in a small number of patients with MDS. 6 Of note, the number of hematogones was enumerated by the percentage of CD34+/CD19+, CD34+/CD24+, CD34+/CD10+, and CD34+/interleukin-7R+ cells, which represented only the most immature compartment of hematogones (stage I hematogones). Similarly, in a recent study by Ogata et al, 9 the number of stage I hematogones was found to be decreased by flow cytometric immunophenotyping in a relatively small number of patients with low-grade MDS.
Although these pilot studies suggested that decreased numbers of stage I hematogones might be a possible diagnostic biomarker for MDS, systematic studies on the diagnostic usefulness of hematogone enumeration in a large cohort of patients with MDS and control subjects are not available. In an attempt to evaluate such practical diagnostic usefulness, we used 3-or 4-color multiparameter flow cytometry (MFC) to compare the percentage of early and total hematogones in the bone marrow (BM) specimens of patients with MDS with those from 2 groups of control subjects (control group 1, most with cytopenia, but without MDS; control group 2, noncytopenic patients undergoing lymphoma staging and with negative BM involvement).
Materials and Methods
Case Identification
We identified 111 nonpediatric MDS cases (study group) by review of our hematopathology database of BM biopsy cases from January 1996 to December 2006 in which a diagnosis of MDS was given (see subsequent diagnostic criteria) and there was a concurrent MFC analysis performed on BM aspirates. Of these, 87 cases (78.4%) also had concurrent cytogenetic studies and 18 (16.2%) had multiple BM biopsy specimens and corresponding MFC analyses.
By using the same approach, we identified 120 nonpediatric control cases from the same period without a history of malignancy. The majority of cases (81 [67.5%]) had a variable degree of cytopenia (control group 1) ❚Table 1❚. However, the cases lacked distinct morphologic dysplasia or/and abnormal cytogenetics to qualify for a diagnosis of MDS. Of the 120 cases, 90 (75.0%) had concurrent cytogenetic studies and 86 of these (95.6%) had a normal karyotype. Of the remaining 4 cases with abnormal clones, 2 had -Y clones (most likely as part of normal aging), 1 had a possible constitutional abnormality (inv(19)(p11q13.3) [30] ), and 1 had an abnormal clone with an add(2)(p21) but lacked distinct morphologic evidence of MDS. None of the patients had a history of malignancies. Therefore, the variation of the number of hematogones related to chemotherapy-induced marrow suppression or postchemotherapy-or BM transplantation-related BM regeneration was not of concern.
Because the number of hematogones is known to fluctuate in a variety of nonneoplastic conditions, such as AIDS and immune dysregulation, [10] [11] [12] [13] which were present in a subset of cases in control group 1, we established an additional control group consisting of 41 cases in which the patients had a recent diagnosis of lymphoma, had not yet received chemotherapy, and had negative staging BM by flow cytometric analysis and morphologic examination.
Clinical information was obtained by review of the electronic charts, submitted clinical diagnoses, and interpretation of MFC results. This study was approved by the University of Texas Southwestern Medical Center at Dallas Institutional Review Board.
MDS was diagnosed in accordance with World Health Organization criteria. 2 Dysplasia was designated as present in a lineage if 10% or more of BM nucleated cells of the corresponding lineage were dysplastic. Other diseases known to cause cytopenia or dysplasia were ruled out by repeated history taking and physical and laboratory examinations. MDS cases were further subclassified into low-grade and highgrade MDS. The former group included refractory anemia and refractory cytopenia with multilineage dysplasia with or without ringed sideroblasts. The latter group included refractory anemia with excess blasts 1 and 2. Cytogenetic studies (conventional karyotype and MDS panel by fluorescence in situ hybridization) were performed using standard methods, as previously described. 14 Cytogenetic abnormalities were classified according to the International System for Human Cytogenetic Nomenclature. 15 
MFC Analysis
All cases were immunophenotyped using 3-color FACScan or 4-color FACSCalibur flow cytometric instruments with CELLQuest software (Becton Dickinson, San Jose, CA) and analyzed using cluster analysis with Paint-aGate Software (Becton Dickinson). More than 90% of cases were analyzed by 4-color MFC. BM processing and antibody staining were performed as previously described. 10 The following monoclonal antibodies (clones) were used in the panels to profile B-cell precursors: CD10 (W8E7), CD14 (MP9), CD19 (SJ25C1), CD20 (L27), CD22 (S-HCL-1), CD34 (8G12), CD38 (HB7), CD45 (2DI), CD71 (L01.1), and glycophorin A [GAR2(HIR-2)]. They were conjugated with 1 of 4 fluorochromes, fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein (PerCP), or allophycocyanin (APC), which are listed as FITC/PE/PerCP/APC in the panels identified in the following paragraph. The panel of antibodies was used differently according to the indications for BM examination. For the cases in the MDS group and control group 1, the combinations of CD10/CD22/CD20/CD34 and CD34/CD14/CD45/CD38 were used. The entire population of hematogones was identified as CD10+/CD22+ and the population of stage I hematogones as CD34+/CD22+/CD20-or CD45 dim+ /CD34+/low forward light scatter. For cases in control group 2, the combinations of CD10/CD19/CD20/CD38 and CD71/glycophorin A/CD34/CD38 were used. The entire population of hematogones was identified as CD10+/CD19+/CD38 uniformly strong+ and the population of stage I hematogones as CD34+/ CD38+/low forward light scatter. Populations of entire hematogones were enumerated as a percentage of total nucleated cells and populations of stage I hematogones as a percentage of total nucleated cells or entire hematogones. Lack of detectable hematogones (below the detection threshold, 0.01%) was reported as 0%.
Statistical Analysis
Statistical analysis was performed using Prism software (version 4.0; GraphPad Software, San Diego, CA). Two tailed Mann-Whitney tests and unpaired t tests were used to evaluate the difference in the median and mean values, respectively, between the control and MDS groups. The Kruskal-Wallis test was used to evaluate the difference in the median values among 3 MDS subgroups. The sensitivity and specificity were analyzed by receiver operating characteristic (ROC) curves. The Fisher exact test was used to analyze categorical variables (eg, sex and presence or absence of hematogones). A P value of less than .05 was considered statistically different.
Results
Patient Characteristics
A total of 111 cases of MDS were analyzed for hematogones in BM aspirate specimens. There were 68 men and 43 women, aged 20 to 87 years (median, 70 years). A total of 120 control cases without MDS were analyzed as one control group. There were 59 men and 61 women, aged 32 to 89 years (median, 49.5 years). The most common indications for flow cytometric study were various cytopenias (81/120 [67.5%]). Other indications are listed in Table 1 . Control group 2 consisted of 41 noncytopenic lymphoma staging cases with negative BM specimens. There were 22 men and 19 women, aged 20 to 78 years (median, 52 years). There were no significant differences in the sex distribution among these 3 groups. Although there were no significant differences in age between the 2 control groups, patients with MDS were significantly older than patients in the control groups (P < .05), necessitating an age-matched comparison using a subset of the control group (as described subsequently).
Low Percentage of Hematogones in MDS Cases Compared With Non-MDS Cases
The median and mean percentages of total hematogones in MDS cases were 0% and 0.100%, respectively, which was significantly lower than those in control group 1 (P < .0001) and control group 2 (P < .0001) ❚Table 2❚ and ❚Figure 1❚. Because the percentage of hematogones was not significantly different between the 2 control groups (P = .235), the subsequent analyses were carried out using only group 1 as the control group.
Because the median age in the MDS group was older than that in control group 1 and it is known that the percentage of hematogones decreases with increasing age, 10 data were reanalyzed in an age-matched manner after excluding data for 13 patients 40 years or younger in control group 1 and for 54 patients 70 years or older in the MDS group. As shown in Table 2 , the lower percentage of hematogones in the MDS group persisted, even after removing age as a confounding factor.
Although the percentage of hematogones was statistically different, there was some overlap in the ranges (Table 2) . If the cutoff for the percentage of hematogones less than 0.045% was chosen for the indication of MDS (in which the sum of sensitivity and specificity was largest), the sensitivity and specificity were 74% (95% confidence interval [CI], 65%-82%) and 73% (95% CI, 64%-81%), respectively. The area under the ROC curve was 0.783 ❚Figure 2A❚. In addition, the absence of detectable hematogones was significantly more common in the MDS group (56/111 [50.5%]) vs that in the control group 1 (27/120 [22.5%]; P < .0001). Of 56 MDS cases without detectable hematogones, 17 (30%) showed no distinct other abnormalities, such as no increase in blasts and no evidence of hypogranular granulocytes or aberrant CD56 expression on granulocytic or monocytic cells.
We next analyzed the percentage of stage I hematogones. Stage I hematogones (CD34+/CD22+/CD20-or CD45 dim+ / CD34+/low forward light scatter) form an easily recognizable cluster with low forward and side light scatter and dim/moderate CD45 expression. Similar to the results of the entire hematogone population, the percentage of stage I hematogones in the MDS group (mean, 0.015% of total events and 2.94% of total hematogones) was significantly lower than that in control group 1 ❚Table 3❚. Similar to the results for the entire hematogone population, the ranges also showed an overlap (Table 3) . If stage I hematogones less than 0.025% of total events was chosen as the cutoff (in which the sum of sensitivity and specificity was the largest), the sensitivity and specificity for the diagnosis of MDS were 92% (95% CI, 85%-96%) and 59% (95% CI, 50%-68%), respectively. The area under the ROC curve was 0.763 ❚Figure 2B❚. Of the cases with detectable stage I hematogones, the percentage of stage I hematogones among the total events was significantly lower in the MDS group (mean, 0.12% vs 0.27% in the control group 1; P < .05), whereas the percentage of stage I hematogones within the entire hematogone population was not significantly different (mean, 25.1% vs 20.7% in the control group; P = .488) ( Table 3) . Representative examples of flow cytometric dot plots in MDS vs control cases are illustrated in ❚Image 1❚. There were 19 cases with multiple longitudinal MFC analyses. Of the patients represented, 14 had persistent MDS and all had a persistently low percentage of hematogones. Four patients had MDS in remission, and all had accordingly increased percentages of hematogones. However, 1 patient had a variable percentage of hematogones (0%-3.5%) despite relapse of MDS.
Lack of Significant Differences in the Percentage of Hematogones in Low-vs High-Grade MDS
We were also interested in whether there was a difference in the percentage of hematogones in early vs advanced MDS. Low-grade MDS included refractory anemia and refractory cytopenia with multilineage dysplasia with or without ringed sideroblasts. As illustrated in ❚Table 4❚, there was no significant difference among these subgroups (P = .438).
Lack of Significant Differences in the Percentage of Hematogones in MDS Cases With or Without Cytogenetic Abnormalities
Of 87 MDS cases with available cytogenetics, 55 (63%) had abnormal cytogenetic results. Although it is known that patients with MDS may have a normal karyotype, for the purpose of this study, we separated MDS cases with clonal cytogenetic abnormalities from cases without clonal abnormalities because the latter subgroup may have questionable secondary and nonprimary myelodysplasia. Interestingly, the percentage of hematogones was not significantly different between these subgroups (mean, 0.14% and 0.10%, respectively; P = .282) ❚Table 5❚, whereas the percentage of hematogones in cytogenetically normal MDS cases was significantly lower than that in the control group 1 (mean, 0.14% vs 0.91%, respectively, P < .01). Furthermore, the frequency of absence of detectable hematogones was not significantly different in MDS cases with normal cytogenetics (19/32 [59%] ) from those with abnormal cytogenetics (39/55 [71%]; P = .347). It thus appears reasonable to include cases with morphologic dysplasia but without clonal abnormalities and without identifiable causes of cytopenias in the MDS group.
Of note, there was 1 case in the control group with an abnormal clone detected by cytogenetic studies [add(2)(p21)] but with no distinct morphologic evidence of MDS. It has been described that cytogenetic abnormalities could be detected in cases suspected clinically to be MDS because of unexplained cytopenia, yet there is no morphologic evidence of dysplasia. 16 In such cases, the karyotypic abnormalities may be evidence of a form fruste of MDS, and, in some cases, morphologic evidence of MDS will appear after variable length of follow-up. Interestingly, this case showed no detectable hematogones and may indeed represent an early evolving MDS.
Discussion
Maturing B-cell precursors, or hematogones, are a subset of normally occurring, immature B-lineage cells that exhibit a typical, consistent, complex spectrum of sequential antigen expression that defines the normal maturation of B-lineage precursors. 10, [17] [18] [19] [20] [21] The earliest recognizable hematogones (stage I) express the progenitor cell marker CD34 in combination with CD19, high levels of CD10 and CD38, low/moderate levels of CD22, and absence of CD20. They progress to the intermediate stage by down-regulating CD34 completely and CD10 partially, with an increase in CD22 and sequential up-regulation of CD20. Finally, CD10 is down-regulated completely and CD38 partially, concomitant with maturation into naive B cells. It has been shown in prior gene expression profiling studies that MDS is associated with down-regulation of B lineage-affiliated genes in BM specimens. [6] [7] [8] In this study, we used MFC to find a significantly low percentage of BM hematogones, either as an entire population or the most immature subset (stage I hematogones), in MDS cases compared with non-MDS control cases. In our study, we addressed this issue in a rather comprehensive manner by including a large number of cases, performing a systematic analysis of total and stage I hematogones, and incorporating comparisons between low-and high-grade MDS and between cases with and without cytogenetic abnormalities. Our results confirm the usefulness of the flow cytometric enumeration of hematogones in the diagnosis of MDS.
The difficulty in exploring the percentage of hematogones as a diagnostic biomarker is how to establish the "control" cases. Hematogones are found in small numbers in the BM of most patients but may be increased in a variety of reactive or regenerative conditions and may be decreased with increasing age, [10] [11] [12] [13] as detailed in the "Materials and Methods" section. Because BM examinations are seldom performed on entirely healthy people, establishing a normal range from adequate numbers of people in different age groups is problematic. To circumvent this variation, we evaluated 2 control groups. One group consisted of mainly cytopenic but non-MDS cases. Although some of the patients' underlying medical conditions would cause an increased number of hematogones, this control cohort is relevant because these cytopenias need to be differentiated clinically from those associated with MDS. The comparison was made between the entire cohort of MDS cases and this group of control cases and also in an age-matched manner to minimize the effect of age as a confounding factor. To further substantiate the validity of the comparison, we established a second control group, representing noncytopenic patients with a recent diagnosis of lymphoma who had negative staging BM results. The percentage of hematogones was consistently lower in the MDS group compared with either control group, indicating that our results truly reflect the status of maturing B-cell precursors in the BM of patients with MDS.
The percentage of hematogones was consistently low in MDS cases in this study. This was manifested as a low percentage of the entire population of hematogones, stage I hematogones, frequent lack of detectable hematogones, and persistently low numbers of hematogones in cases of persistent MDS. However, there was an overlap in the range of hematogones in MDS vs non-MDS BM samples, which was also reflected in nonideal values of the sensitivity and specificity or the area under the ROC curves. Although these results indicate that a low percentage of hematogones alone cannot be used to establish a diagnosis of MDS, this parameter would be greatly useful as a biomarker to aid in a diagnosis in conjunction with other immunophenotypic findings 9,22-24 and morphologic, clinical, and cytogenetic features.
Interestingly, the mean and median percentages of hematogones were not significantly different between lowand high-grade MDS or between MDS with and without chromosomal abnormalities. Moreover, the percentage of hematogones in MDS cases lacking chromosomal abnormalities was lower compared with that in control cases. Taken together, these results may imply that the defect in BM maturing B-cell precursors is an early event in the pathogenesis of MDS, probably before detectable chromosomal abnormalities. This notion is in line with the gene expression profiling studies 6, 8 in which decreased expression of B cell-affiliated genes was found in cytogenetically normal patients with low-grade MDS.
In this study, we focused exclusively on the percentage of hematogones. Immunophenotypic aberrations on CD34+ progenitor cells, granulocytes, and monocytes detected by MFC are increasingly recognized as useful features in the diagnosis of MDS. 9, [22] [23] [24] [25] Of note, a proportion of MDS cases without detectable hematogones (30%) showed no other distinct immunophenotypic abnormalities, such as no increase in blasts and no evidence of hypogranular granulocytes or aberrant CD56 expression on granulocytes or monocytes. This suggests that lack of detectable hematogones in cytopenic patients, although nonspecific, could raise the concern for the possibility of an early MDS, and a systematic workup targeted to that possibility could be initiated.
In previous gene expression profiling studies, 6,8 the authors proposed 2 hypotheses to explain the difference in Blymphoid gene expression in MDS samples, which included a reduction in absolute numbers of hematogones or/and abnormal (reduced) gene expression. The results from our study based on the relatively large number of patients and results from others 9 favor the former notion, although the latter is not formally excluded. These observations raise questions about the earliest B-cell compartment that is altered in size in MDS. The reduction in CD34+/CD19+ cells (stage I hematogones) in patients with early MDS would suggest a defect in the pro-B-cell stage 26 or a stage earlier than the pro-B-cell stage because the numbers of CD34+/interleukin-7R+/CD19-cells are reduced. 27 However, because the earliest cell compartments in human B lymphopoiesis are poorly characterized, it remains to be seen if earlier lymphoid cells are involved.
Although the molecular and cellular mechanisms of MDS are not completely understood, it is tempting to propose several explanations for decreased numbers of maturing B-cell precursors based on current knowledge. First, there may be an increase in myeloid-biased hematopoietic stem cells, which generate reduced numbers of lymphoid progeny. 28 Second, significant levels of apoptosis in BM CD19+ cells in patients with MDS compared with normal BM have been reported. 29 Third, MDS clonal cells, which differentiate into myeloid cells but usually not into B lymphocytes, are predominant in the BM. [30] [31] [32] [33] The failure of B-cell differentiation in MDS would then imply that peripheral mature B cells are derived from residual normal hematopoiesis.
We have demonstrated that the percentage of BM hematogones is significantly low in MDS cases, irrespective of the stage of disease or the presence of chromosomal abnormalities. This finding provides a basis for a diagnostically useful flow cytometric biomarker and has implications for understanding the cell fate decisions of MDS stem cells and progenitor cells. Future prospective studies on a large cohort of patients may help elucidate these issues.
